Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duncan C Gilbert

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
BJU International|October 19, 2016
Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancerDuncan C Gilbert, Trinh Duong, Howard G Kynaston, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2021
Prognostic value of high-risk human papillomavirus DNA and p16<sup>INK4a</sup> immunohistochemistry in patients with anal cancer: An individual patient data meta-analysisTheresa Obermueller, Joris Hautekiet, Maria P Busto, et al.
JCO Precision Oncology|January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE TrialClare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
The Lancet. Oncology|May 7, 2025
Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trialAlexandra Gilbert, Richard Adams, Joanne Webster, et al.
The Lancet. Oncology|April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.
International Journal of Radiation Oncology, Biology, Physics|November 19, 2022
International Validation of the EORTC QLQ-ANL27, a Field Study to Test the Anal Cancer-Specific Health-Related Quality-of-Life QuestionnaireSamantha C Sodergren, Colin D Johnson, Alexandra Gilbert, et al.
Contemporary Clinical Trials|March 27, 2024
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trialsMatthew R Sydes, Macey L Murray, Saiam Ahmed, et al.
Lancet (London, England)|February 14, 2021
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E Langley, Duncan C Gilbert, Trinh Duong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
BJU International|October 19, 2016
Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancerDuncan C Gilbert, Trinh Duong, Howard G Kynaston, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2021
Prognostic value of high-risk human papillomavirus DNA and p16<sup>INK4a</sup> immunohistochemistry in patients with anal cancer: An individual patient data meta-analysisTheresa Obermueller, Joris Hautekiet, Maria P Busto, et al.
JCO Precision Oncology|January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE TrialClare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
The Lancet. Oncology|May 7, 2025
Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trialAlexandra Gilbert, Richard Adams, Joanne Webster, et al.
The Lancet. Oncology|April 30, 2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trialsMahaz Kayani, Laura Murphy, Peter Dutey-Magni, et al.
International Journal of Radiation Oncology, Biology, Physics|November 19, 2022
International Validation of the EORTC QLQ-ANL27, a Field Study to Test the Anal Cancer-Specific Health-Related Quality-of-Life QuestionnaireSamantha C Sodergren, Colin D Johnson, Alexandra Gilbert, et al.
Contemporary Clinical Trials|March 27, 2024
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trialsMatthew R Sydes, Macey L Murray, Saiam Ahmed, et al.
Lancet (London, England)|February 14, 2021
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E Langley, Duncan C Gilbert, Trinh Duong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.
Pageof 6